<p>随着美国市场面临潜在波动，主要股指在政府关门截止日期前经历轻微波动，投资者密切关注可能影响小盘股的经济指标。在这样的环境中，识别基本面强劲且具有增长潜力的鲜为人知的公司，对于那些希望在市场中发现隐藏机会的投资者来说至关重要。</p>
<h3>美国基本面强劲的十大未被发现的宝藏</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Bancorp</td>
<td>75.89%</td>
<td>1.93%</td>
<td>-1.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Senstar Technologies</td>
<td>NA</td>
<td>-18.50%</td>
<td>29.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ASA Gold and Precious Metals</td>
<td>NA</td>
<td>12.79%</td>
<td>-0.59%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sound Financial Bancorp</td>
<td>34.70%</td>
<td>2.11%</td>
<td>-11.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Affinity Bancshares</td>
<td>43.51%</td>
<td>4.54%</td>
<td>8.05%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>SUI Group Holdings</td>
<td>NA</td>
<td>16.40%</td>
<td>-30.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Metalpha Technology Holding</td>
<td>NA</td>
<td>75.66%</td>
<td>28.60%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Valhi</td>
<td>44.30%</td>
<td>1.10%</td>
<td>-1.40%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Rich Sparkle Holdings</td>
<td>26.73%</td>
<td>-6.13%</td>
<td>1.75%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Solesence</td>
<td>91.26%</td>
<td>23.30%</td>
<td>4.70%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国基本面强劲的未被发现的宝藏筛选器中的 286 只股票的完整列表。</p>
<p>以下是筛选器中一些选择的预览。</p>
<h2>Gyre Therapeutics (GYRE)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Gyre Therapeutics, Inc.是一家制药公司，专注于开发和商业化小分子药物，用于针对器官纤维化的抗炎和抗纤维化治疗，市值为 6.5032 亿美元。</p>
<p><strong>运营：</strong> Gyre Therapeutics 主要通过其 Gyre Pharmaceuticals 部门产生收入，该部门报告收入为 1.0219 亿美元。</p>
<p>Gyre Therapeutics 是一家灵活的生物技术公司，最近实现了盈利，但预计未来三年年收益将下降 84.3%。尽管如此，收入预计每年增长近 17%。该公司无债务，且过去的盈利质量高。最近的事件包括其被纳入 S&amp;P 全球 BMI 指数，以及 Ping Zhang 担任临时首席执行官的领导变更。对于 2025 年，Gyre 预计收入在 1.18 亿至 1.28 亿美元之间，受新产品推出如 Etorel 和 Contiva 以及 ETUARY®销售的推动。</p>
<ul>
<li>解锁我们对 Gyre Therapeutics 股票分析的全面见解，详见本健康报告。</li>
<li>探索历史数据，以跟踪 Gyre Therapeutics 随时间的表现，详见我们的过去部分。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 GYRE 收益和收入增长</p>
<h2>HarborOne Bancorp (HONE)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> HarborOne Bancorp, Inc.为个人、家庭、中小型企业和市政当局提供金融服务，市值为 5.5817 亿美元。</p>
<p><strong>运营：</strong> HarborOne Bancorp 主要通过 HarborOne Bank 产生收入，贡献 1.4555 亿美元，以及 HarborOne Mortgage 贡献 1935 万美元。该公司展现出值得注意的净利润率趋势，对整体盈利能力有重要影响。</p>
<p>HarborOne Bancorp 总资产为 56 亿美元，股本为 5.801 亿美元，展现出强大的财务基础。总存款为 45 亿美元，贷款为 47 亿美元，强调了强劲的贷款活动，主要由低风险资金来源支持——89% 来自客户存款。该银行的坏账准备金充足，达到 147%，不良贷款管理良好，比例为 0.7%。过去一年，收益增长了 65.9%，显著超过行业增长率 12.8%。最近，HarborOne 宣布每股季度股息为 0.09 美元，反映出其在稳定的收益表现和高质量的盈利历史中对股东回报的承诺。</p>
<ul>
<li>在我们的健康报告中更深入地了解 HarborOne Bancorp 的潜力。</li>
<li>通过查看我们的历史表现报告，获取 HarborOne Bancorp 的历史表现见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eabf449-2ac8-482e-9d39-8d51fa144fa5/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eabf449-2ac8-482e-9d39-8d51fa144fa5/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 HONE 收益和收入增长</p>
<h2>Spok Holdings (SPOK)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Spok Holdings, Inc.通过其子公司 Spok, Inc.在全球提供医疗通信解决方案，市值为 3.5890 亿美元。</p>
<p><strong>运营：</strong> Spok Holdings 主要通过其临床通信与协作业务产生收入，金额为 1.4074 亿美元。</p>
<p>Spok Holdings 是一家灵活的医疗通信行业参与者，正在向 SaaS 模型过渡，这提升了其经常性收入和利润率。五年来无债务，且交易价格低于其公允价值估计的 56.3%，Spok 似乎被低估。该公司报告 2025 年第二季度的收益，销售额为 1725 万美元，净收入为 455 万美元，显示出较去年增长。尽管有这些积极因素，但无线服务收入下降等挑战依然存在，预计年增长率为 1.1%。该股票的目标价格表明从当前水平（约每股 17.53 美元）有潜在上涨空间。</p>
<ul>
<li>Spok Holdings 向 SaaS 模型的过渡提升了经常性收入和利润率。点击这里探索 Spok Holdings 战略转型的完整叙述。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ffb7b4ca-5fc4-4ff3-9e0d-03de98dd33f7/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ffb7b4ca-5fc4-4ff3-9e0d-03de98dd33f7/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 SPOK 收益和收入增长</p>
<h2>接下来该如何做？</h2>
<ul>
<li>在这里调查我们 286 只具有强大基本面的美国未被发现的优质股票。</li>
<li>是这些公司的股东之一吗？确保您不会被突发情况所困扰，通过在 Simply Wall St 中添加您的投资组合，以便及时获取重大股票动态的提醒。</li>
<li>Simply Wall St 是一款为长期股票投资者设计的革命性应用程序，免费且覆盖全球所有市场。</li>
</ul>
<h2>对其他可能性感兴趣？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

GYRE

Spok控股

<p>美国市场正经历波动，促使投资者寻求基本面强劲的鲜为人知的公司。值得关注的潜在投资机会包括 Gyre Therapeutics、HarborOne Bancorp 和 Spok Holdings，这些公司在市场挑战中展现出增长潜力。Gyre 专注于抗炎药物，HarborOne 提供具有强大利润率的金融服务，而 Spok 则正在向医疗通信的 SaaS 模式转型。这些公司因其稳健的财务状况和增长前景而受到关注，成为寻求市场隐藏机会的投资者的吸引选项</p>

<p>As the U.S. market faces potential volatility with major stock indexes experiencing slight fluctuations ahead of a government shutdown deadline, investors are keenly observing economic indicators that could impact small-cap stocks. In such an environment, identifying lesser-known companies with strong fundamentals and growth potential can be crucial for those looking to uncover hidden opportunities in the market.</p>
<div class="lb-trans"><p>随着美国市场面临潜在波动，主要股指在政府关门截止日期前经历轻微波动，投资者密切关注可能影响小盘股的经济指标。在这样的环境中，识别基本面强劲且具有增长潜力的鲜为人知的公司，对于那些希望在市场中发现隐藏机会的投资者来说至关重要。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals In The United States</h3>
<div class="lb-trans"><h3>美国基本面强劲的十大未被发现的宝藏</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Bancorp</td>
<td>75.89%</td>
<td>1.93%</td>
<td>-1.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Senstar Technologies</td>
<td>NA</td>
<td>-18.50%</td>
<td>29.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ASA Gold and Precious Metals</td>
<td>NA</td>
<td>12.79%</td>
<td>-0.59%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sound Financial Bancorp</td>
<td>34.70%</td>
<td>2.11%</td>
<td>-11.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Affinity Bancshares</td>
<td>43.51%</td>
<td>4.54%</td>
<td>8.05%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>SUI Group Holdings</td>
<td>NA</td>
<td>16.40%</td>
<td>-30.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Metalpha Technology Holding</td>
<td>NA</td>
<td>75.66%</td>
<td>28.60%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Valhi</td>
<td>44.30%</td>
<td>1.10%</td>
<td>-1.40%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Rich Sparkle Holdings</td>
<td>26.73%</td>
<td>-6.13%</td>
<td>1.75%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Solesence</td>
<td>91.26%</td>
<td>23.30%</td>
<td>4.70%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Bancorp</td>
<td>75.89%</td>
<td>1.93%</td>
<td>-1.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Senstar Technologies</td>
<td>NA</td>
<td>-18.50%</td>
<td>29.50%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ASA Gold and Precious Metals</td>
<td>NA</td>
<td>12.79%</td>
<td>-0.59%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sound Financial Bancorp</td>
<td>34.70%</td>
<td>2.11%</td>
<td>-11.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Affinity Bancshares</td>
<td>43.51%</td>
<td>4.54%</td>
<td>8.05%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>SUI Group Holdings</td>
<td>NA</td>
<td>16.40%</td>
<td>-30.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Metalpha Technology Holding</td>
<td>NA</td>
<td>75.66%</td>
<td>28.60%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Valhi</td>
<td>44.30%</td>
<td>1.10%</td>
<td>-1.40%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Rich Sparkle Holdings</td>
<td>26.73%</td>
<td>-6.13%</td>
<td>1.75%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Solesence</td>
<td>91.26%</td>
<td>23.30%</td>
<td>4.70%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 286 stocks from our US Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国基本面强劲的未被发现的宝藏筛选器中的 286 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是筛选器中一些选择的预览。</p>
</div><h2>Gyre Therapeutics (GYRE)</h2>
<div class="lb-trans"><h2>Gyre Therapeutics (GYRE)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for anti-inflammatory and anti-fibrotic treatments targeting organ fibrosis, with a market cap of $650.32 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Gyre Therapeutics, Inc.是一家制药公司，专注于开发和商业化小分子药物，用于针对器官纤维化的抗炎和抗纤维化治疗，市值为 6.5032 亿美元。</p>
</div><p><strong>Operations:</strong> Gyre Therapeutics generates revenue primarily through its Gyre Pharmaceuticals segment, which reported $102.19 million in revenue.</p>
<div class="lb-trans"><p><strong>运营：</strong> Gyre Therapeutics 主要通过其 Gyre Pharmaceuticals 部门产生收入，该部门报告收入为 1.0219 亿美元。</p>
</div><p>Gyre Therapeutics, a nimble player in the biotech scene, has recently become profitable, yet faces a forecasted earnings dip of 84.3% annually over the next three years. Despite this, revenue is expected to grow by nearly 17% per year. The company remains debt-free and boasts high-quality past earnings. Recent events include its addition to the S&amp;P Global BMI Index and leadership changes with Ping Zhang stepping in as interim CEO. For 2025, Gyre anticipates revenues between US$118 million and US$128 million, fueled by new product launches like Etorel and Contiva alongside ETUARY® sales.</p>
<div class="lb-trans"><p>Gyre Therapeutics 是一家灵活的生物技术公司，最近实现了盈利，但预计未来三年年收益将下降 84.3%。尽管如此，收入预计每年增长近 17%。该公司无债务，且过去的盈利质量高。最近的事件包括其被纳入 S&amp;P 全球 BMI 指数，以及 Ping Zhang 担任临时首席执行官的领导变更。对于 2025 年，Gyre 预计收入在 1.18 亿至 1.28 亿美元之间，受新产品推出如 Etorel 和 Contiva 以及 ETUARY®销售的推动。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Gyre Therapeutics stock in this health report.</li>
<li>Explore historical data to track Gyre Therapeutics' performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对 Gyre Therapeutics 股票分析的全面见解，详见本健康报告。</li>
<li>探索历史数据，以跟踪 Gyre Therapeutics 随时间的表现，详见我们的过去部分。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/97ccc20e-42f8-49ae-93d0-40fda938d4d8/chart/earnings-and-revenue-growth"/></p>
<p>GYRE Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 GYRE 收益和收入增长</p>
</div><h2>HarborOne Bancorp (HONE)</h2>
<div class="lb-trans"><h2>HarborOne Bancorp (HONE)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> HarborOne Bancorp, Inc. offers financial services to individuals, families, small and mid-size businesses, and municipalities with a market capitalization of $558.17 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> HarborOne Bancorp, Inc.为个人、家庭、中小型企业和市政当局提供金融服务，市值为 5.5817 亿美元。</p>
</div><p><strong>Operations:</strong> HarborOne Bancorp generates revenue primarily through HarborOne Bank, contributing $145.55 million, and HarborOne Mortgage with $19.35 million. The company exhibits a net profit margin trend worth noting for its implications on overall profitability.</p>
<div class="lb-trans"><p><strong>运营：</strong> HarborOne Bancorp 主要通过 HarborOne Bank 产生收入，贡献 1.4555 亿美元，以及 HarborOne Mortgage 贡献 1935 万美元。该公司展现出值得注意的净利润率趋势，对整体盈利能力有重要影响。</p>
</div><p>HarborOne Bancorp, with total assets of US$5.6 billion and equity of US$580.1 million, showcases a robust financial foundation. Total deposits stand at US$4.5 billion against loans of US$4.7 billion, underlining strong lending activity supported by primarily low-risk funding sources—89% from customer deposits. The bank's allowance for bad loans is sufficient at 147%, with non-performing loans well-managed at 0.7%. Earnings have surged by 65.9% over the past year, notably outpacing the industry growth rate of 12.8%. Recently, HarborOne declared a quarterly dividend of $0.09 per share, reflecting its commitment to shareholder returns amidst steady earnings performance and high-quality earnings history.</p>
<div class="lb-trans"><p>HarborOne Bancorp 总资产为 56 亿美元，股本为 5.801 亿美元，展现出强大的财务基础。总存款为 45 亿美元，贷款为 47 亿美元，强调了强劲的贷款活动，主要由低风险资金来源支持——89% 来自客户存款。该银行的坏账准备金充足，达到 147%，不良贷款管理良好，比例为 0.7%。过去一年，收益增长了 65.9%，显著超过行业增长率 12.8%。最近，HarborOne 宣布每股季度股息为 0.09 美元，反映出其在稳定的收益表现和高质量的盈利历史中对股东回报的承诺。</p>
</div><ul>
<li>Take a closer look at HarborOne Bancorp's potential here in our health report.</li>
<li>Gain insights into HarborOne Bancorp's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的健康报告中更深入地了解 HarborOne Bancorp 的潜力。</li>
<li>通过查看我们的历史表现报告，获取 HarborOne Bancorp 的历史表现见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eabf449-2ac8-482e-9d39-8d51fa144fa5/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/9eabf449-2ac8-482e-9d39-8d51fa144fa5/chart/earnings-and-revenue-growth"/></p>
<p>HONE Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 HONE 收益和收入增长</p>
</div><h2>Spok Holdings (SPOK)</h2>
<div class="lb-trans"><h2>Spok Holdings (SPOK)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Spok Holdings, Inc. offers healthcare communication solutions globally through its subsidiary, Spok, Inc., and has a market capitalization of $358.90 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Spok Holdings, Inc.通过其子公司 Spok, Inc.在全球提供医疗通信解决方案，市值为 3.5890 亿美元。</p>
</div><p><strong>Operations:</strong> Spok Holdings generates revenue primarily from its Clinical Communication and Collaboration business, amounting to $140.74 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> Spok Holdings 主要通过其临床通信与协作业务产生收入，金额为 1.4074 亿美元。</p>
</div><p>Spok Holdings, a nimble player in the healthcare communication sector, is navigating a transition to a SaaS model, which is boosting its recurring revenue and margins. With no debt for five years and trading at 56.3% below its fair value estimate, Spok seems undervalued. The company reported Q2 2025 earnings with sales of US$17.25 million and net income of US$4.55 million, showing growth from the previous year. Despite these positives, challenges like declining wireless service revenue persist alongside modest projected annual growth of 1.1%. The stock's target price suggests potential upside from current levels around US$17.53 per share.</p>
<div class="lb-trans"><p>Spok Holdings 是一家灵活的医疗通信行业参与者，正在向 SaaS 模型过渡，这提升了其经常性收入和利润率。五年来无债务，且交易价格低于其公允价值估计的 56.3%，Spok 似乎被低估。该公司报告 2025 年第二季度的收益，销售额为 1725 万美元，净收入为 455 万美元，显示出较去年增长。尽管有这些积极因素，但无线服务收入下降等挑战依然存在，预计年增长率为 1.1%。该股票的目标价格表明从当前水平（约每股 17.53 美元）有潜在上涨空间。</p>
</div><ul>
<li>Spok Holdings' transition to a SaaS model boosts recurring revenue and margins. Click here to explore the full narrative on Spok Holdings' strategic shift.</li>
</ul>
<div class="lb-trans"><ul>
<li>Spok Holdings 向 SaaS 模型的过渡提升了经常性收入和利润率。点击这里探索 Spok Holdings 战略转型的完整叙述。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ffb7b4ca-5fc4-4ff3-9e0d-03de98dd33f7/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/ffb7b4ca-5fc4-4ff3-9e0d-03de98dd33f7/chart/earnings-and-revenue-growth"/></p>
<p>SPOK Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SPOK 收益和收入增长</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下来该如何做？</h2>
</div><ul>
<li>Investigate our full lineup of 286 US Undiscovered Gems With Strong Fundamentals right here.</li>
<li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li>
<li>Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里调查我们 286 只具有强大基本面的美国未被发现的优质股票。</li>
<li>是这些公司的股东之一吗？确保您不会被突发情况所困扰，通过在 Simply Wall St 中添加您的投资组合，以便及时获取重大股票动态的提醒。</li>
<li>Simply Wall St 是一款为长期股票投资者设计的革命性应用程序，免费且覆盖全球所有市场。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>对其他可能性感兴趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

发掘美国市场中的 3 个尚未被发现的瑰宝